Accelerate CGT developement with strategic viral vector manufacturing and CDMO partnerships that balance quality, cost, and speed from bench to clinic.

Next step in a broader collaboration to support VVMF build viral vector manufacturing capabilities Oxford, UK – 18 March 2026: OXB (LSE: OXB), a ...

The SK pharmteco group is now offering a standardized viral vector and plasmid manufacturing process to a global audience. The global approach can help customers move to batches for clinical trials in ...

Although the targets of biomanufacturing have evolved from therapeutic proteins to “advanced therapies” and now to gene therapies, the issues and solutions remain the same. The production of safe, ...

Viral vector-based cell therapy uses modified viruses to deliver a healthy gene into a cell to treat a disease. The virus’ shell delivers the gene and the vectors, with the genetic information they ...

Oxford, UK – 11 March 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or the “Company"), a leading gene and cell therapy group, is pleased to announce that it has completed its deal with ...

-- Viral Vector Facility Further Strengthens Vertical Integration of Kite’s Global CAR T-cell Therapy Manufacturing Network, Supports Growing Demand of Company’s Blood Cancer Treatments -- -- Kite is ...

SK pharmteco today announced a significant funding commitment to support strategic initiatives within its viral vector ...

Advances company’s ambition to provide fully integrated and comprehensive solution for viral vector manufacturing Mirus Bio’s leading GMP transfection reagents complement company’s upstream ...

Intensified methods of viral vector manufacture and development of novel analytical methods for viral vector characterization. Collaborations with industrial and academic partners to further develop ...

Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first commercial viral vector Contract Development and Manufacturing Organisation (CDMO), today announces that it has entered into a ...